Open Access

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX‑4 chemotherapy

  • Authors:
    • Song‑Hee Han
    • Jin Won Kim
    • Milim Kim
    • Jee Hyun Kim
    • Keun‑Wook Lee
    • Bo‑Hyung Kim
    • Heung‑Kwon Oh
    • Duck‑Woo Kim
    • Sung‑Bum Kang
    • Hyunchul Kim
    • Eun Shin
  • View Affiliations

  • Published online on: April 9, 2019     https://doi.org/10.3892/ol.2019.10234
  • Pages: 5572-5580
  • Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer stem cell (CSC) and ATP‑binding cassette (ABC) transporters are associated with treatment resistance and outcomes of patients with cancer. The present study investigated the prognostic implications of pre‑therapeutic expression of ABC transporters and CSC markers in patients with colon cancer (CC) who received adjuvant 5‑fluorouracil, leucovorin and oxaliplatin combination therapy (FOLFOX‑4). The immunohistochemical expression of 3 ABC transporters, including ABC subfamily C member 2 (ABCC2), ABCC3 and ABC subfamily G member 2 (ABCG2), and 3 CSC markers, including sex determining region Y‑box 2 (SOX2), leucine‑rich repeat‑containing G protein‑coupled receptor 5 and aldehyde dehydrogenase 1, were determined in 164 CC tissues from patients with stage III CC, who underwent postoperative FOLFOX‑4 chemotherapy. The association between the protein expression and patients' prognoses was statistically analyzed. ABCG2 was associated with favorable overall survival rate (OS; P=0.001), and ABCC2, ABCG2 and SOX2 were associated with increased disease‑free survival rate (DFS; P=0.001, 0.002 and 0.013, respectively). In multivariate analyses, ABCG2 was an independent prognostic factor for OS [hazard ratio (HR)=2.877; P=0.046], and ABCC2 and SOX2 were independent prognostic factors for DFS (HR=2.831; P=0.014; HR=2.558, P=0.020, respectively). ABCC2, ABCG2 and SOX2 may be promising prognostic markers for patients with CC receiving FOLFOX‑4 therapy.
View Figures
View References

Related Articles

Journal Cover

June-2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Han SH, Kim JW, Kim M, Kim JH, Lee KW, Kim BH, Oh HK, Kim DW, Kang SB, Kim H, Kim H, et al: Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX‑4 chemotherapy. Oncol Lett 17: 5572-5580, 2019
APA
Han, S., Kim, J.W., Kim, M., Kim, J.H., Lee, K., Kim, B. ... Shin, E. (2019). Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX‑4 chemotherapy. Oncology Letters, 17, 5572-5580. https://doi.org/10.3892/ol.2019.10234
MLA
Han, S., Kim, J. W., Kim, M., Kim, J. H., Lee, K., Kim, B., Oh, H., Kim, D., Kang, S., Kim, H., Shin, E."Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX‑4 chemotherapy". Oncology Letters 17.6 (2019): 5572-5580.
Chicago
Han, S., Kim, J. W., Kim, M., Kim, J. H., Lee, K., Kim, B., Oh, H., Kim, D., Kang, S., Kim, H., Shin, E."Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX‑4 chemotherapy". Oncology Letters 17, no. 6 (2019): 5572-5580. https://doi.org/10.3892/ol.2019.10234